Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Sep 18;5(3):152-162.
doi: 10.1016/S2055-6640(20)30045-5.

What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study

Affiliations
Editorial

What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study

Marion Fiorentino et al. J Virus Erad. .

Abstract

Objectives: Enrolling people living with HIV with undetectable viral load into HIV cure-related clinical trials (HCRCT) is challenging. Few data are currently available about the individual factors that influence willingness to participate in HCRCT (WPHCRCT). We hypothesised that WPHCRCT would be more frequent among people living with HIV considering themselves HIV activists. The objective of this study was to investigate the individual characteristics associated with both WPHCRCT and self-identification as an HIV activist.

Methods: The study enrolled 195 long-term ART-treated and virologically suppressed people living with HIV, followed-up in 19 French HIV services, 2016-2017. A Bayesian model averaging approach was used to assess correlates of both outcomes i.e. WPHCRCT and self-identified HIV activism.

Results: WPHCRCT was reported by 43% of participants and was positively associated with self-identification as an HIV activist (adjusted odds ratio [aOR] 2.90 95% confidence interval [CI] 2.17-3.63], P<0.05) and self-confidence as an HIV positive person (aOR 1.17, 95% CI 0.99-1.35, P<0.1). Self-identified HIV activists (56% of participants) were more likely to have a higher 'relationship with others' score using the post-traumatic growth inventory (aOR 1.10, 95% CI 0.99-1.20, P<0.1), to obtain information about HIV from a greater number of sources (aOR 1.35 [95% CI 1.00-1.68], P<0.1), and to feel greatly affected by mandatory daily treatment (aOR 2.15, 95% CI 1.27-3.03, P<0.1). All associations had relative importance weight>0.75, indicating strong evidence.

Conclusions: WPHCRCT is strongly related to HIV activism, and also to positive psychosocial characteristics as a person living with HIV, especially regarding relationships with others. The desire to contribute to the fight against HIV for the sake of the HIV community and society should be taken into account to improve participation in upcoming HCRCT.

Keywords: France; HIV; activism; cure research; cure trial; willingness to participate in clinical trials.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Significant associations with willingness to participate in a HIV-cure related trial (analysis 1, n=195, multimodel averaging method) and with self-identification as an HIV activist (analysis 2, n=195, multimodel averaging method) Significant associations *P<0.1, **P<0.05, ***P<0.01 and RIW indicating positive evidence [0.75–0.90] and strong evidence ≥0.90. The exhaustive results of analyses 1 and 2 are available in the supplementary tables. aOR: adjusted odds ratio; RIW: relative importance weights. Following HIV diagnosis.

References

    1. Woods S, McCormack P.. Disputing the ethics of research: the challenge from bioethics and patient activism to the interpretation of the Declaration of Helsinki in clinical trials. Bioethics 2013; 27: 243– 250. - PubMed
    1. Cox LE, Rouff JR, Svendsen KH et al. . Community advisory boards: their role in AIDS clinical trials. Health Soc Work 1998; 23: 290– 297. - PubMed
    1. Barbot J. How to build an ‘active’ patient? The work of AIDS associations in France. Soc Sci Med 2006; 62: 538– 551. - PubMed
    1. Barré-Sinoussi F, Ross AL, Delfraissy JF.. Past, present and future: 30 years of HIV research. Nat Rev Microbiol 2013; 11: 877– 883. - PubMed
    1. Antiretrovial Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293– 299. - PMC - PubMed

Publication types